Hypogonadism and Testosterone Therapy: Associations With Cardiovascular Risk

被引:2
|
作者
Maganty, Avinash [1 ]
Osterberg, E. Charles [1 ]
Ramasamy, Ranjith [2 ]
机构
[1] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA
[2] Baylor Coll Med, Houston, TX 77030 USA
关键词
testosterone replacement therapy (TRT); cardiovascular risk; CORONARY-ARTERY-DISEASE; HEART-FAILURE; DOUBLE-BLIND; OLDER MEN; MORTALITY; EVENTS; METAANALYSIS; REPLACEMENT; DEFICIENCY; ANDROGENS;
D O I
10.1177/1557988314540933
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Testosterone replacement therapy (TRT) use is increasing, primarily in men with symptomatic hypogonadism. There are many benefits associated with TRT use, including improved sexual function, improved bone mineral density, and increased free fat mass and strength. As TRT use increases, its role on cardiovascular health must be explored. While previous evidence identified no adverse cardiovascular risks associated with TRT use, more recent studies suggest that there may be an associated risk, especially in elderly men and younger men with cardiac disease. Care must be taken with TRT use in these groups of men by careful monitoring for cardiac dysfunction. While testosterone therapy has many benefits and may generally be well tolerated, those prescribing the therapy must be cognizant of the potential adverse cardiovascular risks and advise men on the potential risks versus benefits.
引用
收藏
页码:340 / 344
页数:5
相关论文
共 50 条
  • [41] Testosterone Replacement Therapy and the Risk of Prostate Cancer in Men With Late-Onset Hypogonadism
    Santella, Christina
    Renoux, Christel
    Yin, Hui
    Yu, Oriana H. Y.
    Azoulay, Laurent
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2019, 188 (09) : 1666 - 1673
  • [42] Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer?
    Gould, DC
    Kirby, RS
    PROSTATE CANCER AND PROSTATIC DISEASES, 2006, 9 (01) : 14 - 18
  • [43] COST EFFECTIVENESS OF TESTOSTERONE UNDECANOATE INJECTION AS TESTOSTERONE THERAPY FOR MALE HYPOGONADISM
    Ferguson, J.
    Gilmour, I.
    Church, N.
    Priaulx, J.
    JOURNAL OF MENS HEALTH, 2009, 6 (03) : 251 - 251
  • [44] ARE THE ALTERNATIVE THERAPY FOR HYPOGONADISM AS EFFECTIVE AS CONVENTIONAL TESTOSTERONE(T) THERAPY
    Habous, M.
    Badwan, A.
    Elborai, S.
    Nassar, M.
    Williamson, B.
    Muir, G.
    JOURNAL OF SEXUAL MEDICINE, 2013, 10 : 260 - 260
  • [45] Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer?
    D C Gould
    R S Kirby
    Prostate Cancer and Prostatic Diseases, 2006, 9 : 14 - 18
  • [46] CPAP - THERAPY AND TESTOSTERONE REPLACEMENT THERAPY AS PREVENTION OF CARDIOVASCULAR DISEASES IN MIDDLE-AGED MEN WITH SLEEP APNEA AND HYPOGONADISM
    Madaeva, I.
    Berdina, O.
    Semenova, N.
    Madaev, V.
    Ryachkova, L.
    Kolesnikova, L.
    SLEEP MEDICINE, 2017, 40 : E205 - E205
  • [47] Testosterone and cardiovascular risk
    Giacomo Tirabassi
    Angelo Gioia
    Lara Giovannini
    Marco Boscaro
    Giovanni Corona
    Angelo Carpi
    Mario Maggi
    Giancarlo Balercia
    Internal and Emergency Medicine, 2013, 8 : 65 - 69
  • [48] Testosterone and cardiovascular risk
    Tirabassi, Giacomo
    Gioia, Angelo
    Giovannini, Lara
    Boscaro, Marco
    Corona, Giovanni
    Carpi, Angelo
    Maggi, Mario
    Balercia, Giancarlo
    INTERNAL AND EMERGENCY MEDICINE, 2013, 8 : S65 - S69
  • [49] Testosterone and cardiovascular risk
    Schooling, C. Mary
    Leung, Gabriel M.
    LANCET DIABETES & ENDOCRINOLOGY, 2015, 3 (09): : 682 - 682
  • [50] Testosterone and cardiovascular risk
    不详
    EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE, 2023, (197): : 431 - 431